The latest financial statement is for the quarter ending 2025-12-31.
| Cash Flow | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net (loss) income | -10,584 | 1,965 | -13,562 |
| Depreciation and amortization | 885 | 803 | 5,377 |
| Impairment expense | - | - | 8,263 |
| Stock-based compensation expense | 283 | 114 | 576 |
| Derivative warrant liabilities loss (gain) | -8,244 | 3,784 | -1,703 |
| Amortization of debt discount and issuance costs | 29 | 29 | 108 |
| Inventory write-down | 835 | 278 | 325 |
| Non-cash loss on extinguishment of debt | - | - | 0 |
| Other non-cash adjustments | 0 | 0 | -752 |
| Non-cash adjustments from discontinued operations | 0 | 0 | 254 |
| Accounts receivable, net | -2,302 | 2,070 | 7,629 |
| Inventories | -609 | -1,056 | -382 |
| Prepaid expenses and other current assets | 1,483 | -484 | 451 |
| Accounts payable | -1,083 | 1,741 | 287 |
| Accrued liabilities | 3,456 | -1,637 | 886 |
| Other operating assets and liabilities, net | -182 | -403 | -528 |
| Changes in operating assets and liabilities from discontinued operations | 0 | 0 | -264 |
| Net cash provided by operating activities | 3,675 | -618 | -1,937 |
| Cash received from sales of fixed assets | 0 | 0 | 668 |
| Cash payments for fixed asset purchases | 17 | 0 | 228 |
| Cash payments for acquired intangible assets | - | - | 3,000 |
| Net cash (used in) provided by investing activities | -17 | 0 | -2,560 |
| Net proceeds from issuance of common stock and warrants | - | - | 14,840 |
| Net proceeds received from revolving credit facility | -5,798 | 5,810 | 6,668 |
| Payment made to fixed payment arrangements | 0 | 3,050 | 6,016 |
| Payments made to borrowings | 465 | 464 | 1,857 |
| Proceeds from borrowings | - | - | 1,857 |
| Payments for debt issuance costs | - | - | 49 |
| Net cash used in financing activities | -6,263 | 2,296 | 15,443 |
| Net change in cash and cash equivalents | -2,605 | 1,678 | 10,946 |
| Cash and cash equivalents at beginning of period | 32,630 | 30,952 | 20,006 |
| Cash and cash equivalents at end of period | 30,025 | 32,630 | 30,952 |
AYTU BIOPHARMA, INC (AYTU)
AYTU BIOPHARMA, INC (AYTU)